163 related articles for article (PubMed ID: 23302769)
1. Bivalent promoter marks and a latent enhancer may prime the leukaemia oncogene LMO1 for ectopic expression in T-cell leukaemia.
Oram SH; Thoms J; Sive JI; Calero-Nieto FJ; Kinston SJ; Schütte J; Knezevic K; Lock RB; Pimanda JE; Göttgens B
Leukemia; 2013 Jun; 27(6):1348-57. PubMed ID: 23302769
[TBL] [Abstract][Full Text] [Related]
2. A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients.
Oram SH; Thoms JA; Pridans C; Janes ME; Kinston SJ; Anand S; Landry JR; Lock RB; Jayaraman PS; Huntly BJ; Pimanda JE; Göttgens B
Oncogene; 2010 Oct; 29(43):5796-808. PubMed ID: 20676125
[TBL] [Abstract][Full Text] [Related]
3. APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL.
Li Z; Abraham BJ; Berezovskaya A; Farah N; Liu Y; Leon T; Fielding A; Tan SH; Sanda T; Weintraub AS; Li B; Shen S; Zhang J; Mansour MR; Young RA; Look AT
Leukemia; 2017 Oct; 31(10):2057-2064. PubMed ID: 28260788
[TBL] [Abstract][Full Text] [Related]
4. SCL, LMO1 and Notch1 reprogram thymocytes into self-renewing cells.
Gerby B; Tremblay CS; Tremblay M; Rojas-Sutterlin S; Herblot S; Hébert J; Sauvageau G; Lemieux S; Lécuyer E; Veiga DF; Hoang T
PLoS Genet; 2014 Dec; 10(12):e1004768. PubMed ID: 25522233
[TBL] [Abstract][Full Text] [Related]
5. Modeling T-cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes.
Tremblay M; Tremblay CS; Herblot S; Aplan PD; Hébert J; Perreault C; Hoang T
Genes Dev; 2010 Jun; 24(11):1093-105. PubMed ID: 20516195
[TBL] [Abstract][Full Text] [Related]
6. Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism.
Oldridge DA; Wood AC; Weichert-Leahey N; Crimmins I; Sussman R; Winter C; McDaniel LD; Diamond M; Hart LS; Zhu S; Durbin AD; Abraham BJ; Anders L; Tian L; Zhang S; Wei JS; Khan J; Bramlett K; Rahman N; Capasso M; Iolascon A; Gerhard DS; Guidry Auvil JM; Young RA; Hakonarson H; Diskin SJ; Look AT; Maris JM
Nature; 2015 Dec; 528(7582):418-21. PubMed ID: 26560027
[TBL] [Abstract][Full Text] [Related]
7. SCL/TAL1: a multifaceted regulator from blood development to disease.
Porcher C; Chagraoui H; Kristiansen MS
Blood; 2017 Apr; 129(15):2051-2060. PubMed ID: 28179281
[TBL] [Abstract][Full Text] [Related]
8. An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice.
Aplan PD; Jones CA; Chervinsky DS; Zhao X; Ellsworth M; Wu C; McGuire EA; Gross KW
EMBO J; 1997 May; 16(9):2408-19. PubMed ID: 9171354
[TBL] [Abstract][Full Text] [Related]
9. ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer.
Thoms JA; Birger Y; Foster S; Knezevic K; Kirschenbaum Y; Chandrakanthan V; Jonquieres G; Spensberger D; Wong JW; Oram SH; Kinston SJ; Groner Y; Lock R; MacKenzie KL; Göttgens B; Izraeli S; Pimanda JE
Blood; 2011 Jun; 117(26):7079-89. PubMed ID: 21536859
[TBL] [Abstract][Full Text] [Related]
10. scid Thymocytes with TCRbeta gene rearrangements are targets for the oncogenic effect of SCL and LMO1 transgenes.
Chervinsky DS; Lam DH; Melman MP; Gross KW; Aplan PD
Cancer Res; 2001 Sep; 61(17):6382-7. PubMed ID: 11522630
[TBL] [Abstract][Full Text] [Related]
11. OLIG2 (BHLHB1), a bHLH transcription factor, contributes to leukemogenesis in concert with LMO1.
Lin YW; Deveney R; Barbara M; Iscove NN; Nimer SD; Slape C; Aplan PD
Cancer Res; 2005 Aug; 65(16):7151-8. PubMed ID: 16103065
[TBL] [Abstract][Full Text] [Related]
12. Disordered T-cell development and T-cell malignancies in SCL LMO1 double-transgenic mice: parallels with E2A-deficient mice.
Chervinsky DS; Zhao XF; Lam DH; Ellsworth M; Gross KW; Aplan PD
Mol Cell Biol; 1999 Jul; 19(7):5025-35. PubMed ID: 10373552
[TBL] [Abstract][Full Text] [Related]
13. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
[TBL] [Abstract][Full Text] [Related]
14. TAL1 activation in T-cell acute lymphoblastic leukemia: a novel oncogenic 3' neo-enhancer.
Smith C; Goyal A; Weichenhan D; Allemand E; Mayakonda A; Toprak U; Riedel A; Balducci E; Manojkumar M; Pejkovska A; Mücke O; Sollier E; Bakr A; Breuer K; Lutsik P; Hermine O; Spicuglia S; Asnafi V; Plass C; Touzart A
Haematologica; 2023 May; 108(5):1259-1271. PubMed ID: 36632736
[TBL] [Abstract][Full Text] [Related]
15. Generation of Inducible
Przybylski GK; Korsak D; Iżykowska K; Nowicka K; Zalewski T; Tubacka M; Mosor M; Januszkiewicz-Lewandowska D; Frydrychowicz M; Boruczkowski M; Dworacki G; van den Brandt J; Grabarczyk P; Schmidt CA; Zeng C; Li Y
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563322
[TBL] [Abstract][Full Text] [Related]
16. LMO1 is a novel oncogene in lung cancer, and its overexpression is a new predictive marker for anti-EGFR therapy.
Zhang Y; Yang J; Wang J; Guo H; Jing N
Med Oncol; 2014 Aug; 31(8):99. PubMed ID: 25037573
[TBL] [Abstract][Full Text] [Related]
17. LMO1 is a novel oncogene in colorectal cancer and its overexpression is a new predictive marker for anti-EGFR therapy.
Liu J; Yan P; Jing N; Yang J
Tumour Biol; 2014 Aug; 35(8):8161-7. PubMed ID: 24845030
[TBL] [Abstract][Full Text] [Related]
18. The enhancer RNA
Tan SH; Leong WZ; Ngoc PCT; Tan TK; Bertulfo FC; Lim MC; An O; Li Z; Yeoh AEJ; Fullwood MJ; Tenen DG; Sanda T
Blood; 2019 Jul; 134(3):239-251. PubMed ID: 31076442
[TBL] [Abstract][Full Text] [Related]
19. NKX3.1 is a direct TAL1 target gene that mediates proliferation of TAL1-expressing human T cell acute lymphoblastic leukemia.
Kusy S; Gerby B; Goardon N; Gault N; Ferri F; Gérard D; Armstrong F; Ballerini P; Cayuela JM; Baruchel A; Pflumio F; Roméo PH
J Exp Med; 2010 Sep; 207(10):2141-56. PubMed ID: 20855495
[TBL] [Abstract][Full Text] [Related]
20. The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia.
Mansour MR; Sanda T; Lawton LN; Li X; Kreslavsky T; Novina CD; Brand M; Gutierrez A; Kelliher MA; Jamieson CH; von Boehmer H; Young RA; Look AT
J Exp Med; 2013 Jul; 210(8):1545-57. PubMed ID: 23857984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
